MYC and cancer: The senolytic compound Dasatinib, which suppresses anti-apoptotic signaling by interfering with the activity of several protein kinases [48], efficiently and selectively eliminated GNE/BMS-treated senescent KRASG12V/MYC cancer cells, but not the control cells (Fig. 4J, K).